TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Price, Quote, News and Overview
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD
TEVA Quote, Performance and Key Statistics
TEVA PHARMACEUTICAL-SP ADR
NYSE:TEVA (1/23/2025, 7:00:00 PM)
After market: 21.79 0 (0%)21.79
-0.22 (-1%)
The current stock price of TEVA is 21.79 USD. In the past month the price decreased by -1.36%. In the past year, price increased by 82.96%.
TEVA Latest News, Press Releases and Analysis
Promising Signs: TEVA PHARMACEUTICAL-SP ADR Setting the Stage for a Breakout.
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) has a good technical rating of 10 out of 10 and could possibly break out.
FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
Teva Challenges Drug Price Law's Impact On Innovation, Generics
Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, and innovation, disrupting healthcare balance.
Teva annonce un partenariat en vue de commercialiser le candidat biosimilaire de Formycon à Eylea® (aflibercept) dans la majeure partie de l’Europe et en Israël
Klinge Biopharma GmbH (Klinge) détient les droits exclusifs de la commercialisation mondiale de FYB203, le candidat biosimilaire de Formycon, à ...
Teva gibt Zusammenarbeit zur Vermarktung des Formycon Biosimilar-Kandidaten für Eylea® (Aflibercept) in großen Teilen Europas und in Israel bekannt
Klinge Biopharma GmbH (Klinge) besitzt die exklusiven weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kandidat für Eylea®1Die Vereinbarung...
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
TEVA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 75.38 | 727.75B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.21 | 360.19B | ||
| JNJ | JOHNSON & JOHNSON | 14.68 | 353.05B | ||
| MRK | MERCK & CO. INC. | 16.24 | 244.44B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.01 | 212.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.41 | 199.99B | ||
| PFE | PFIZER INC | 10.25 | 149.84B | ||
| SNY | SANOFI-ADR | 12.41 | 130.32B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.55 | 119.95B | ||
| ZTS | ZOETIS INC | 28.99 | 75.33B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 69.47B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B |
Related screens
About TEVA
Company Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Company Info
TEVA PHARMACEUTICAL-SP ADR
124 Dvora Hanevi'a St.
TEL AVIV-YAFO 49131 IL
CEO: Kare Schultz
Employees: 35001
Company Website: https://www.tevapharm.com/
Investor Relations: https://ir.tevapharm.com/
Phone: 97239148213
TEVA FAQ
What is the price of TEVA?
The current price of TEVA is 21.79 USD.
What is the symbol for TEVA PHARMACEUTICAL-SP ADR?
The exchange symbol of TEVA PHARMACEUTICAL-SP ADR is TEVA and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is TEVA listed?
TEVA is listed on the New York Stock Exchange, Inc. exchange.
Is TEVA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TEVA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TEVA.
Does TEVA pay dividends?
TEVA does not pay a dividend.
When does TEVA report earnings?
TEVA will report earnings on 2025-01-29, after the market close.
What is the Price/Earnings (PE) ratio of TEVA?
The PE ratio for TEVA is 7.84. This is based on the reported non-GAAP earnings per share of 2.78 and the current share price of 21.79 USD.
What is the Short Interest ratio of TEVA?
The outstanding short interest for TEVA is 2.41% of its float.
TEVA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TEVA. When comparing the yearly performance of all stocks, TEVA is one of the better performing stocks in the market, outperforming 92.25% of all stocks.
TEVA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TEVA. TEVA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
TEVA Financial Highlights
Over the last trailing twelve months TEVA reported a non-GAAP Earnings per Share(EPS) of 2.78. The EPS decreased by 22.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.15% | ||
| ROE | -7.49% | ||
| Debt/Equity | 2.61 |
TEVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 42% to TEVA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -2.98% and a revenue growth 7.14% for TEVA